Replies to post #5431 on BioCurex, Inc.(fka BOCX)

[reversetaxman]

You have made the specific statement that BOCX has received other offers, please tell all who they were from and where we can find that information so that we may review it.

[Gold Seeker]

Erthang: "One fact I will tell you is that Biocurex has received more offers (plural), but Biocurex turned them down because they were not as attractive as the Abbott deal"

I agree. Moro thought he could get equal or better deals with others. He could not, obviously because the royalties offered were lower. ABT has provisions for equal royalties in sublicenses.

"The reason for the small initial payment is because the deal is back loaded with the milestone payment and a fairly large percentage of the revenue from sales, comparatively speaking."

This one, I will not agree with. Moro desperately needed up front cash. If upfront money was sacrificed to get higher royalties, that was short sighted but as Bocxman said, Moro is not much of a business man. With the deal he made with ABT, there is no further need to make other deals. ABT can sell or sublicense about all the tests that would ever be needed. It would take an exclusive to get up front money so that option is gone for all others. ABT has gotten exactly what they needed and wanted. Basically, they have an exclusive for no up front money and they can play with it until late 2007 at no cost. Pretty smart move on Abbott's part.